Evidence map›Paper›PMID 38148577›Full record

ArticleCancer reports (Hoboken, N.J.)2023

Exploring the intratumoral heterogeneity of DNA ploidy in prostate cancer.

Tatjana Vlajnic, David C Müller, Christian Ruiz, René Schönegg, Hans-Helge Seifert, George N Thalmann, Tobias Zellweger, Clémentine Le Magnen, Cyrill A Rentsch, Lukas Bubendorf

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer reports (Hoboken, N.J.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Tatjana VlajnicInstitute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland.ORCID https://orcid.org/0000-0002-1067-6771
David C MüllerInstitute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland.
Christian RuizInstitute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland.
René SchöneggInstitute of Pathology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
Hans-Helge SeifertDepartment of Urology, University Hospital Basel, University of Basel, Basel, Switzerland.
George N ThalmannDepartment of Urology, Inselspital, University Hospital Bern, Bern, Switzerland.
Tobias ZellwegerDivision of Urology, St. Clara Hospital, Basel, Switzerland.
Clémentine Le MagnenInstitute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland.
Cyrill A RentschDepartment of Urology, University Hospital Basel, University of Basel, Basel, Switzerland.
Lukas BubendorfInstitute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland.
University of Basel · CHSt. Claraspital · CHUniversity Hospital of Bern · CHUniversity of St.Gallen · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProstate cancer is morphologically and molecularly heterogeneous. Genomic heterogeneity might be mirrored by variability in DNA ploidy. Aneuploidy is a hallmark of genomic instability and associated with tumor aggressiveness. Little attention has been paid to the biological significance of the diploid tumor cell population that often coexists with aneuploid populations. Here, we investigated the role of DNA ploidy in tumor heterogeneity and clonal evolution.

methodsThree radical prostatectomy specimens with intratumoral heterogeneity based on nuclear features on H&E were selected. DNA content of each subpopulation was determined by DNA image cytometry and silver in situ hybridization (SISH). Genomic evolution was inferred from array comparative genomic hybridization (aCGH). Additionally, immunohistochemistry was used to examine the stemness-associated marker ALDH1A1.

resultsNuclear morphology reliably predicted DNA ploidy status in all three cases. In one case, aCGH analysis revealed several shared deletions and one amplification in both the diploid and the aneuploid population, suggesting that these populations could be related. In the other two cases, a statement about relatedness was not possible. Furthermore, ALDH1A1 was expressed in 2/3 cases and exclusively observed in their diploid populations.

conclusionsIn this proof-of-concept study, we demonstrate the feasibility to predict the DNA ploidy status of distinct populations within one tumor by H&E morphology. Future studies are needed to further investigate the clonal relationship between the diploid and the aneuploid subpopulation and test the hypothesis that the aneuploid population is derived from the diploid one. Finally, our analyses pointed to an enrichment of the stemness-associated marker ALDH1A1 in diploid populations, which warrants further investigation in future studies.

Indexed as

clonal evolutionheterogeneityploidyprostate cancer

Identifiers

PMID38148577
PMCPMC10849929
OpenAlexW4390271963

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.